BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38765899)

  • 1.
    Vieira JO; Pesquero JB; Nazário ACP
    Breast Care (Basel); 2024 Apr; 19(2):96-105. PubMed ID: 38765899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
    Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
    Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
    Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
    Huang L; Lang GT; Liu Q; Shi JX; Shao ZM; Cao AY
    Ann Transl Med; 2021 Feb; 9(4):301. PubMed ID: 33708928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Carcinoma Using Image-Guided Clip Placement.
    Pandurangappa V; Paruthy SB; Jamwal R; Singh A; Tanwar S; Kumar D; Pal S; Mohan SK; Das A; Trs PR
    Cureus; 2023 Oct; 15(10):e47763. PubMed ID: 38021852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients.
    Nairuz T; Bushra YU; Kabir Y
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):3809-3815. PubMed ID: 34967559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
    Kim KI; Lee KH; Kim TR; Chun YS; Lee TH; Park HK
    J Breast Cancer; 2014 Mar; 17(1):40-6. PubMed ID: 24744796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differences between clinical response and pathologic response of breast cancer after neoadjuvant chemotherapy].
    Zheng S; Zhang BL; Zhang RZ; Yang JL; Zou SM; Xue LY; Luo W; Yuan YL; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):734-8. PubMed ID: 21215162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
    Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
    Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the response to neoadjuvant chemotherapy in patients with breast cancer using ultrasound scattering coefficient: A preliminary report.
    Dobruch-Sobczak K; Piotrzkowska-Wróblewska H; Klimoda Z; Secomski W; Karwat P; Markiewicz-Grodzicka E; Kolasińska-Ćwikła A; Roszkowska-Purska K; Litniewski J
    J Ultrason; 2019; 19(77):89-97. PubMed ID: 31355579
    [No Abstract]   [Full Text] [Related]  

  • 13. The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case-control study.
    Dong MJ; Wang LB; Jiang ZN; Jin M; Hu WX; Shen JG
    Onco Targets Ther; 2014; 7():1963-9. PubMed ID: 25368523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
    Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
    Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
    Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
    Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
    J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Takahashi S; Sasaki K; Ishioka C
    Breast Cancer (Auckl); 2023; 17():11782234231167655. PubMed ID: 37181950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
    Subbiah S; Gopu G; Senthilkumar P; Muniasamy P
    Indian J Cancer; 2017; 54(4):652-657. PubMed ID: 30082552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.